Plasma CCL5 promotes EMT-medicated epirubicin-resistance in locally advanced breast cancer. - Ma, Ge; Huang, Huaxing; Li, Minghui; Li, Li; Kong, Peng; Zhu, Yichao; Xia, Tiansong; Wang, Shui (Cancer Biomarkers, 2018)